Takara Bio Inc. (TYO:4974)
929.00
+10.00 (1.09%)
Sep 12, 2025, 3:30 PM JST
Takara Bio Revenue
Takara Bio had revenue of 9.27B JPY in the quarter ending June 30, 2025, with 9.10% growth. This brings the company's revenue in the last twelve months to 45.81B, up 6.98% year-over-year. In the fiscal year ending March 31, 2025, Takara Bio had annual revenue of 45.04B with 3.53% growth.
Revenue (ttm)
45.81B
Revenue Growth
+6.98%
P/S Ratio
2.44
Revenue / Employee
25.75M
Employees
1,779
Market Cap
111.87B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 45.04B | 1.53B | 3.53% |
Mar 31, 2024 | 43.51B | -34.64B | -44.33% |
Mar 31, 2023 | 78.14B | 10.44B | 15.43% |
Mar 31, 2022 | 67.70B | 21.61B | 46.90% |
Mar 31, 2021 | 46.09B | 11.52B | 33.33% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.21B |
Takeda Pharmaceutical Company | 4,480.25B |
HOYA Corporation | 876.09B |
Daiichi Sankyo Company | 1,924.68B |
Otsuka Holdings | 2,401.70B |
Terumo | 1,037.94B |
Astellas Pharma | 1,944.99B |
Shionogi & | 440.50B |